



SPAFID  
CONNECT

|   |   |            |
|---|---|------------|
| Informazione<br>Regolamentata n.<br>20106-14-2021 | Data/Ora Ricezione<br>31 Marzo 2021<br>18:22:36 | MTA - Star |
|---|---|------------|

Societa' : Pharmanutra S.p.A.  
Identificativo : 144584  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN02 - Lacorte Roberto  
Tipologia : REGEM  
Data/Ora Ricezione : 31 Marzo 2021 18:22:36  
Data/Ora Inizio : 31 Marzo 2021 18:22:37  
Diffusione presunta  
Oggetto : PR - PHARMANUTRA SPA shareholders  
meeting documents

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A.: FILING OF DOCUMENTS FOR THE SHAREHOLDERS' MEETING

*Pisa, 31st March 2021* – **PharmaNutra S.p.A.** announces that the Annual Financial Report, including the Consolidated Financial Statements at December 31, 2020, the Company's draft Financial Statements at December 31, 2020, the related Report on Operations (which, as provided by Article 40 paragraph 2 *bis* of Legislative Decree 127/1991, was drawn up in a single document) the attestations required by Article 154-bis, paragraph 5, of Legislative Decree No. 58 of February 24, 1998 ("TUF"), the Statutory Auditors' Reports and the Independent Auditors' Reports, as well as the Report on Corporate Governance and Ownership Structure are available in the registered office in Pisa, via delle Lenze 216/b, on the Company website [www.pharmanutra.it](http://www.pharmanutra.it), and in the authorised storage mechanism "eMarket Storage" on the website [www.emarketstorage.com](http://www.emarketstorage.com).

**PharmaNutra S.p.A.**

*Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 112 studies published involving more than 7000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.*

[PharmaNutra.it](http://PharmaNutra.it)

For further information:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-14

Numero di Pagine: 4